T-cell for Immunotherapy Development
Based on our advanced technology platform, extensive experience in pharmacology and preclinical studies, Creative Biolabs provides customized powerful risk-based preclinical data verification services for developing drugs in T-cell therapy according to your specific needs in a timely and cost-effective manner.
Introduction of T-cell Therapy
T-cell, a type of cell in the immune system, is the primary killing cell in vivo; it can protect the body by destroying abnormal cells, including cancers. The receptor redirection of antigen specificity is usually based on T-cells genetically modified to express either CAR-T (Chimeric Antibody Receptor Engineered T Cell) and genetically modified T cell receptors (Gene Modified TCR). These two T-cell therapy techniques are commonalities based on improving the ability of T cell receptors to recognize and attack specific antigenic cell antigens through genetic modification. Given the abilities of T-cells to recognize and kill target cells, most investigations of T-cell therapy have obtained impressive results in targeting chronic viruses and multiple types of cancer. Such therapies aim mostly at boosting the adaptive immune responses against cancer and chronic infections.
T cell receptors (TCRs) can recognize tumor-specific proteins on the inside of cells. This type of immunotherapy must be highly personalized and will require both the identification of candidate neoantigens from the tumor exome or proteome and the retrieval or generation of the cognate TCR recognition sequences for T-cell genetic engineering. A growing number of tumor-associated antigens are being identified, and the most oncogenic proteins are intracellular, the development and engineering of a panel of TCRs with specific responses to oncogenic driver proteins have great appeal.
CAR T cell therapy is a type of cell therapy that is one type of adoptive cell therapy. These new receptors, called chimeric antigen receptors (CARs), recognize proteins expressed on the surface and allow the T cells to recognize cancer cells better. They become activated to kill their target. CAR T cell therapy is being studied in the treatment of some types of cancer. A sample of a patient's T-cells are collected from the blood, then modified to produce special structures on their surface called CARs. When these CAR T cells are reinfused into the patient, the CARs enable them to latch onto a specific antigen on the patient's tumor cells and kill them.
Fig.1 CAR T cell therapy. (June, 2018)
Our Service for T-Cell Therapy
The outcome of recent trials suggests that T-cell therapy could have produced encouraging results in the therapy for a variety of diseases; it is a possibility to offer a standardized, quality-controlled, regulatory-body-approved treatment for the cell therapies. Although clinical success has been achieved in a number of tumor types, like all cell therapies, T-cell therapy can cause several worrisome severely restricting the development of T cells, and sometimes fatal, risks of significant side effects. Possible side effects from CAR T-cell therapy include cytokine release syndrome (CRS), neurologic difficulties and significant on- and off-target toxicity.
Combination of expertise in T-cell therapy and different disease studies, Creative Biolabs provides professional drug development consulting service for T-cell therapy research. Creative Biolabs can also deal with data reproducibility crisis to reduce the failure and high risk of investment and to confirm the accuracy and repeatability of preclinical experiments. Furthermore, as a leading contract research organization, Creative Biolabs offers comprehensive and trustworthy project feasibility assessment to help you make reasonable decisions to reduce investment risk and speed up the drug research and development projects for T-cell therapy.
Creative Biolabs will provide customized solutions to our clients to meet your specific needs with high-quality and high efficiency. There is no doubt that we will be your professional and reliable partner. Please feel free to contact us for more detailed information on your specific project requirements.
June, C. H.; et al. CAR T cell immunotherapy for human cancer. Science. 2018, 359(6382): 1361-1365.